[Update on Diabetic Kidney Disease 2018].

The first descriptions of diabetes mellitus are known as "sweet honey urine". Interestingly, the new therapy of diabetic kidney disease, namely SGLT-2-inhibitor, enhances glucosuria, leading to the historical description of sweet urine. This not only leads to a better control of glycemia itself, but it also leads to a better renal prognosis by reducing glomerular hyperfiltration. So far, this effect has been proven for diabetic kidney disease in type 2 diabetic patients. Whether this effect could also lead to a better renal prognosis in other kidney diseases with hyperfiltration (independent of hyperglycemia), is still object of ongoing studies.